Asymchem Oligonucleotide Capabilities: End-To-End Drug Development

Asymchem Oligonucleotide Capabilities: End-to-end drug development

Asymchem Drug Product Capabilities

Drug Development Process - TOX, ADME, PK/PD, Clinical POC and Drug Approval

Oligonucleotide Therapeutics Society

History of Asymchem

Asymchem TJ3 Introduction

ChemOutsourcing Tiffany Brock, Senior Director, Business Development Asymchem

The Knowledge Hub TV

Regulatory Applications of a Nonclinical Database for Oligonucleotide Therapeutics at U.S. FDA

Oligonucleotide Therapeutics Society

Sustainability in peptide and oligonucleotide manufacturing | Aspen API

Informa Connect Life Sciences

What does it take to manufacture oligonucleotides? | Exploration Science

CEM Corporation

Machine learning in drug discovery at Bayer Pharmaceuticals: from models to molecules

Weights & Biases

Optimizing oligonucleotide manufacturing with Asahi Kasei

Informa Connect Life Sciences

Pharma's grand challenge: Developing cost-effective and sustainable oligonucleotide manufacturing

CPI

Genomics throughout the Drug Development Process

IQVIA Laboratories

Recent developments in oligonucleotide analysis: an interview with Zamas Lam

Bioanalysis Zone

About Asymchem

Chemical and Nanotechnology based Approaches to Build Next gen Oligonucleotide Therapeutics

Oligonucleotide Therapeutics Society

UK collaboration aiming to revolutionise oligonucleotide medicines manufacturing

CPI

Druggability and the druggable genome

European Bioinformatics Institute - EMBL-EBI

Thomas Metcalfe-Precision Medicine Approaches and the Future of Drug Development in Oncology